Skip to main content
Figure 3 | Respiratory Research

Figure 3

From: Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial

Figure 3

Clinical efficacy of moxifloxacin vs placebo. (a) Per-protocol end-of-treatment (PP EOT) and intent-to-treat (ITT) populations according to the primary and secondary definitions of an exacerbation, and (b) patients with purulent/mucopurulent sputum at baseline (PP EOT and ITT populations using the primary definition of an exacerbation). The first set of p-values on the graphs are from logistic regression analysis using the median value for patients missing at 48 weeks. Corresponding p-values for logistic regression analysis using last observation carried forward are given in brackets. AECB, acute exacerbation of chronic bronchitis.

Back to article page